These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38863646)

  • 1. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe.
    He C; Guo Y; Zhou N; Wang Z; Liu T; Xu X; Wang F; Zhu H; Yang Z; Yang X; Xia L
    Int J Nanomedicine; 2024; 19():5479-5492. PubMed ID: 38863646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer.
    Xia L; Meng X; Wen L; Zhou N; Liu T; Xu X; Wang F; Cheng Z; Yang Z; Zhu H
    Small; 2021 May; 17(21):e2100378. PubMed ID: 33870644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
    Du Y; Liang X; Li Y; Sun T; Xue H; Jin Z; Tian J
    Cancer Lett; 2018 Feb; 414():230-238. PubMed ID: 29175457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
    Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
    Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of T cell co-regulator factor B7-H3 with
    Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
    Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
    Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
    Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
    Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
    Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging diagnosis and efficacy monitoring by [
    He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
    Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer.
    Xia L; Guo X; Liu T; Xu X; Jiang J; Wang F; Cheng Z; Zhu H; Yang Z
    Nanoscale; 2019 Aug; 11(30):14400-14409. PubMed ID: 31334537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MnCO
    Lee KK; Lee JH; Lee SC; Lee CS
    Theranostics; 2022; 12(15):6762-6778. PubMed ID: 36185599
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of [
    Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
    Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
    Luo X; Peng X; Hou J; Wu S; Shen J; Wang L
    Int J Nanomedicine; 2017; 12():5331-5343. PubMed ID: 28794626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.